Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WCK 5107 Alone and in Combination With Cefepime Administered as Single IV Doses in Healthy Human Volunteers

Trial Profile

Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WCK 5107 Alone and in Combination With Cefepime Administered as Single IV Doses in Healthy Human Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2016

At a glance

  • Drugs Zidebactam (Primary) ; Cefepime
  • Indications Gram-negative infections
  • Focus Adverse reactions
  • Sponsors Wockhardt
  • Most Recent Events

    • 30 Oct 2016 Results assessing safety and pharmacokinetics of Zidebactam presented at the IDWeek 2016
    • 02 May 2016 Status changed from active, no longer recruiting to completed.
    • 28 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top